Format

Send to

Choose Destination
Gynecol Oncol Rep. 2018 May 23;25:37-40. doi: 10.1016/j.gore.2018.05.009. eCollection 2018 Aug.

Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report.

Author information

1
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States.
2
Immunomedics, Inc., 300 The American Road, Morris Plains, NJ 07950, United States.

Abstract

Background:

Uterine serous carcinoma (USC) is a biologically aggressive variant of uterine cancer. Effective treatment options for recurrent, chemotherapy-resistant USC are extremely limited.

Case:

We describe a 74-year-old woman with recurrent and widespread treatment-resistant disease, who experienced a dramatic response to sacituzumab govitecan, a novel antibody-drug conjugate (ADC) targeting human trophoblast-cell-surface antigen (TROP-2), after failing multiple chemotherapy and immunotherapy. The impressive clinical response (66% reduction of target lesions by RECIST 1.1 with a duration response of over 10 months) was confirmed with serial CT scans in the absence of significant adverse events.

Conclusion:

Sacituzumab govitecan may present a new treatment option for recurrent USC patients harboring Trop-2+ tumors resistant to chemotherapy. Clinical trials with sacituzumab govitecan are warranted.

KEYWORDS:

IMMU-132; Recurrent; Sacituzumab govitecan; Treatment-resistant; Uterine serous carcinoma

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center